Skip to content
Spiritual Quotes – Lifestyle
Author:
NOVO NORDISK INC.
Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
November 16, 2026
Novo’s CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
November 15, 2026
Novo’s Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
November 14, 2026
Novo’s investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
November 14, 2026
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician’s real-life “Walk, Golf, and Wegovy®” diet and weight-loss routine
November 12, 2026
Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
November 8, 2026
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
November 6, 2026
Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world
October 29, 2026
Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026
October 28, 2026
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
October 21, 2026
1
2
Next Page
→